Journal

What's Coming Next: CagriSema, Higher-Dose Semaglutide and the 2026 Pipeline

Four new agents or formulations reached or approached approval in 2026. Here is what each would actually change.

Why 2026 is being called a turning point

Four new agents or formulations reached or approached approval within the year: the Wegovy pill in December 2025, Foundayo in April 2026, with CagriSema and a higher-dose semaglutide formulation behind them. For a category that had two injectable options eighteen months ago, that is a structural change in choice.

CagriSema

CagriSema combines cagrilintide, a long-acting amylin analogue, with semaglutide. Amylin is a separate hormonal pathway from GLP-1, and the combination hypothesis is that acting on both produces more effect than either alone — the same logic that produced tirzepatide's dual GIP/GLP-1 mechanism.

It is the furthest along of the next wave, with an FDA response expected during 2026, and has been studied against tirzepatide in head-to-head work as well as in the REDEFINE programme in type 2 diabetes.

It is not approved. No provider can lawfully supply it, and no compounder can either.

Higher-dose semaglutide

A 7.2 mg semaglutide formulation drew attention at ADA 2026 through the STEP UP trial. The approved weight-management dose is 2.4 mg, so this is roughly three times that.

The interest is straightforward: if effect rises with dose within a tolerable range, a higher dose narrows the gap against tirzepatide. Whether tolerability holds at that level is the question the trial exists to answer.

Beyond weight: where the indications are going

The category keeps expanding into adjacent conditions. Zepbound now carries an obstructive sleep apnoea indication alongside weight management. Knee osteoarthritis outcomes improved with semaglutide in 2026 data, with meaningful pain reduction and less analgesic use — and tirzepatide's larger weight loss produced similar pain benefit, which raises the question of whether the effect is weight-dependent or something else. Peripheral artery disease and further heart failure indications are in development.

The warning that belongs on this page

Investigational compounds attract a grey market. Retatrutide is the current example: phase 3 figures circulate widely online, and the sources are frequently peptide vendors rather than publications. We have declined to publish a retatrutide phase 3 number for that reason.

Anything sold today as CagriSema, retatrutide or 7.2 mg semaglutide is outside the approved supply chain entirely. Not compounded-but-legal — outside it. There is no prescriber, no pharmacy licence and no recourse attached to that purchase.

What this means if you are choosing now

A pipeline is not a treatment. If you need treatment now, the decision is between what is approved and available today, and waiting for an unapproved agent is a decision with its own costs.

What the pipeline should change is your view of commitment length. Twelve-month prepayments are common in this market, and the approved landscape has changed materially twice within eighteen months. That is an argument for keeping the exit open — month-to-month pricing costs more per month and buys the ability to switch when something better arrives.

Why combination approaches keep appearing

The pattern across this field is additive mechanisms. Semaglutide acts on GLP-1. Tirzepatide adds GIP and outperformed it head-to-head in SURMOUNT-5. Retatrutide adds glucagon. CagriSema adds amylin through a different hormone entirely.

Each addition is a bet that a separate pathway contributes something the others do not. Tirzepatide's result validated the bet once. Whether it generalises is what the current pipeline is testing.

The dose-escalation alternative

Semaglutide 7.2 mg takes a different route: rather than adding a mechanism, it increases exposure to an established one. The approved weight-management dose is 2.4 mg, so this is roughly three times it.

The question is tolerability. Gastrointestinal effects are dose-related in this class, and the trial exists to find out whether the efficacy gain survives the side-effect burden.

What a new approval would actually change for a patient

Less than the coverage implies, at first. New approvals launch at brand pricing, insurance coverage takes time to establish, and formulary position lags approval by quarters rather than weeks.

The Wegovy pill and Foundayo are useful precedents: both launched with self-pay pricing from $149 and savings programmes bringing eligible commercially insured patients to around $25. That pattern is now familiar enough to expect, but it is not immediate.

How to think about timing

If treatment is clinically indicated now, waiting for an unapproved agent has real costs — untreated time is not neutral. What the pipeline genuinely argues for is avoiding long commitments: the approved landscape has changed materially twice in eighteen months, and a twelve-month prepayment made today forecloses a market still in motion.

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.

Questions readers actually ask